Carole Ho
CIK 1724605 · Chief Medical Officer · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.56M
Companies
4
Total Filings
99
Lifetime Open-Market Net
-$13.21M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RPRX | Director | 13,103 | $59.18 | $775.4K | $0 | 2 | 2026-06-08 |
| DNLI | Chief Medical Officer | 242,391 | $23.85 | $5.78M | -$13.21M | 66 | 2025-08-14 |
| BEAM | Director | — | $26.02 | — | $0 | 5 | 2025-06-06 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | — | $1.54 | — | $0 | 5 | 2024-04-08 |
Recent Filings · Page 8 of 10
99 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-30 | DNLI | Mixed | −5,265 | -$251.6K | EDGAR |
| 2020-10-13 | DNLI | Mixed | — | -$1.88M | EDGAR |
| 2020-09-14 | DNLI | Sell (S) | −3,689 | -$114.4K | EDGAR |
| 2020-08-24 | DNLI | Mixed | +3,689 | -$64.2K | EDGAR |
| 2020-08-20 | DNLI | Grant (A) | — | $0 | EDGAR |
| 2020-06-09 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-01 | DNLI | Sell (S) | −1,428 | -$27.8K | EDGAR |
| 2020-04-01 | DNLI | Exer (M) | +4,250 | $0 | EDGAR |
| 2020-02-12 | DNLI | Grant (A) | — | $0 | EDGAR |
| 2019-12-23 | DNLI | Sell (S) | −6,890 | -$137.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.